Capricor Therapeutics (CAPR) Q3 2024 earnings summary

Executive summary

• Progress made toward filing a BLA for deramiocel (CAP-1002) for DMD cardiomyopathy, with strong clinical data and FDA collaboration; rolling BLA submission initiated in October 2024, full submission expected by year-end, and potential PDUFA date in H2 2025.

• Multiple clinical trials, including HOPE-2 and HOPE-3, have shown positive efficacy and safety data for deramiocel, supporting regulatory filings in the US, Europe, and Japan.

• Commercial preparations underway with NS Pharma, including manufacturing scale-up, market access planning, and global expansion through agreements with Nippon Shinyaku.

• Expanded StealthX exosome platform, including a COVID-19 vaccine candidate selected for Project NextGen, with a Phase 1 trial planned for 2025.

• Completed $86 million public offering, with cash runway expected to support operations into 2027.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $85 million as of September 30, 2024; pro forma total is $166 million after a public offering.

• Q3 2024 revenue was $2.3 million, down from $6.2 million in Q3 2023; nine-month revenue was $11.1 million, down from $13.1 million year-over-year.

• Q3 2024 net loss was $12.6 million ($0.38/share), compared to $6.4 million ($0.25/share) in Q3 2023; nine-month net loss was $33.4 million versus $21.5 million in the prior year period.

• Operating expenses rose to $15.3 million in Q3 2024 (from $13.1 million), driven by R&D and G&A increases.

• Total assets increased to $93.0 million as of September 30, 2024, from $58.7 million at year-end 2023.

Outlook and guidance

• Full BLA submission for deramiocel on track for year-end 2024; FDA decision expected by end of Q1 2025 or H2 2025.

• Cash runway expected to support planned operations into 2027, excluding additional milestone payments or strategic capital use.

• Anticipated rapid adoption of deramiocel if approved, with initial commercial patients transferring from open-label extension groups.

• Manufacturing expansion planned to meet projected demand, including a new facility within a year of launch.

• Indication expansion into Becker muscular dystrophy and further exosome platform development targeted for 2025.